Avaleht › Ülekaalulisus › Alabama › Birmingham
Ülekaalulisus kliinilised uuringud linnas Birmingham, AL
16 uuringut haiguse Ülekaalulisus jaoks otsivad osalejaid linnas Birmingham ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
VärbamineFaas 3
- Univ of Alabama Birmingham, Birmingham
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
VärbamineFaas 2
- University of Alabama - Birmingham, Birmingham
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
VärbamineFaas 3
- Univ of Alabama Birmingham, Birmingham
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
VärbamineFaas 3
- Central Research Associates, Birmingham
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
VärbamineFaas 3
- Birmingham Clinical Research, Birmingham
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
VärbamineFaas 3
- Birmingham Clinical Research, Birmingham
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
VärbamineFaas 3
- AURORA-1 Clinical Site, Birmingham
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
VärbamineFaas 3
- AURORA-2 Clinical Site, Birmingham
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
VärbamineFaas 3
- Alabama Clinical Therapeutics, Birmingham
- University of Alabama at Birmingham, Birmingham
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
VärbamineFaas 3Terved vabatahtlikud oodatud
- ACCOMPLISH-2 Research Site, Birmingham
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
VärbamineFaas 3
- Uni of Alabama at Birmingham, Birmingham
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
VärbamineFaas 3
- Kailera Clinical Site, Birmingham
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
VärbamineFaas 3
- ACCOMPLISH-1 Research Site, Birmingham
- ACCOMPLISH-1 Research Site, Birmingham
Time-restricted Eating for Postpartum Weight Loss
Värbamine
- University of Alabama at Birmingham, Birmingham
Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
Värbamine
- University of Alabama at Birmingham, Birmingham
FELLAShip to Better Health
Värbamine
- The Worship Center Cristian Church, Birmingham
Ülekaalulisus uuringud teistes linnades
- San Antonio, TX34 uuringut
- Houston, TX33 uuringut
- Chicago, IL28 uuringut
- Orlando, FL27 uuringut
- Las Vegas, NV23 uuringut
- Miami, FL23 uuringut
- Atlanta, GA20 uuringut
- Dallas, TX20 uuringut
- New York City, NY19 uuringut
- Jacksonville, FL19 uuringut
- Washington, DC19 uuringut
- Austin, TX18 uuringut
Muud uuringud linnas Birmingham
- Vähk (kõik liigid)30 uuringut
- Rinnavähk24 uuringut
- Rasvumine23 uuringut
- Munasarjavähk23 uuringut
- Mitteväikerakuline kopsuvähk22 uuringut
- Äge müeloidne leukeemia21 uuringut
- Müeloom18 uuringut
- KOKH17 uuringut
- Kardiovaskulaarsed haigused17 uuringut
- Endomeetriumivähk16 uuringut
- 2. tüüpi diabeet16 uuringut
- Tsüstiline fibroos16 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.